Pilot study finds continuous temperature monitoring devices improve early detection of neutropenic fever and cytokine release syndrome in inpatient setting.
This pilot study explored the acceptability and feasibility of two continuous temperature monitoring devices, CORE® and TempTraq®, in 15 inpatients at risk of neutropenic fever (NF) or cytokine release syndrome (CRS) after chemotherapy, stem cell transplant or chimeric antigen receptor (CAR) T cells. Each device was worn for a median of ≥95% of the study, correlated with tympanic temperature and exhibited potential for early detection of NF or CRS ( ClinicalTrials.gov NCT05203809).
No takes yet. Share an insight, caveat, or question.
Fyfe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: